** Shares of digital healthcare services platform Phreesia PHR.N slump 26.64% to $8.37 premarket

** Co lowered fiscal 2027 revenue outlook due to reduced pharma client spending commitments

** Co lowers FY 2027 revenue outlook to $510 mln-$520 mln from $545 mln-$559 mln

** J.P. Morgan downgraded the stock to “neutral” from “overweight” and cut PT, while D.A. Davidson also lowered its PT.

** J.P. Morgan says co’s strategy to slow subscription pricing to bolster retention makes sense, but shifting focus toward the more uncertain Network Solutions business appears poorly timed

** 20 analysts rate the stock "buy" on average; median PT is $25 - data compiled by LSEG

** As of last day's close, co shares have dropped 32.6% YTD, underperforming the S&P 500's .SPX 7.3% fall